Ask AI
See Activity Collection
ProCE Banner Activity

Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape

Podcast

The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Listen to this podcast with 2 experts discussing current gaps and clinical needs for patients with relapsed ES-SCLC, the scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC, the expanding role of antibody–drug conjugates (ADCs) and T-cell engagers in ES-SCLC including recent efficacy and safety data for B7-H3–directed ADCs such as ifinatamab deruxtecan (I-DXd) in ES-SCLC and the strengths and limitations of the available evidence. The experts synthesize this information along with their clinical experiences to illustrate how they are individualizing the care of patients with ES-SCLC based on patient-specific characteristics that influence the selection and sequencing of treatment with a case-based discussion. They close with a reminder of the importance of discussing ongoing trials of investigational B7-H3–directed ADCs and other therapies in ES-SCLC with the goal of continuing to improve outcomes for patients with this disease.

Released: September 10, 2026

Review Activity

Share

Faculty

Charles Rudin

Charles Rudin, MD, PhD

Cancer Center Director
Memorial Sloan Kettering Cancer Center
New York, New York
Mark A. Socinski

Mark A. Socinski, MD

Executive Medical Director
AdventHealth Cancer Institute
Orlando, Florida

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Daiichi Sankyo, Inc. and Merck Sharp & Dohme LLC.

Daiichi Sankyo, Inc.

Merck Sharp & Dohme LLC

Target Audience

This activity is intended for oncologists, pulmonologists, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with extensive-stage small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate B7-H3–directed ADCs from other available and emerging ES-SCLC strategies, including DLL3-directed T-cell engagement, chemotherapy-based approaches, maintenance strategies, and clinical trials, based on mechanism, evidence strength, toxicity profile, and operational feasibility

  • Apply emerging efficacy and safety data for investigational B7-H3–directed ADCs to patient-specific treatment planning after platinum-based therapy, including considerations related to platinum-free interval, disease tempo, brain metastases, ECOG performance status, pulmonary comorbidity, prior thoracic radiation, marrow reserve, prior therapy, and access to specialized monitoring

  • Implement practical monitoring and management strategies for ADC-associated adverse events, including ILD/pneumonitis, cytopenias, gastrointestinal adverse events, fatigue, and infusion-related considerations

  • Use case-based decision-making to formulate sequencing, referral, and multidisciplinary management strategies for patients with relapsed ES-SCLC

Financial Disclosures

Primary Author

Charles Rudin, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Daiichi Sankyo, Genentech, Merck, Novartis.

Mark A. Socinski, MD: grant/research support (paid to institution): BeOne, Cullinan, Elephas, Enliven, Florida Department of Health, Loxo Oncology, Mirati, Nuvalent, Nuvation, OncoC4, Pfizer, Roche (Genentech), Summit; consultant/advisor: AbbVie, Akumin, AstraZeneca, Avistone, Bayer, BeOne, BioNTech, Blueprint, Coherus, Cor2Ed, Daiichi Sankyo, EMD Serono, Foundation, G1 Therapeutics, Gilead, Gritstone, GSK, Merck, Novartis, Novocure, Nuvalent, Nuvation, OncoC4, Partner Therapeutics, Pfizer, Taiho, Takeda, Veracyte, Verastem; data and safety monitoring board/steering committee: BeOne, Bristol Myers Squibb, Genentech, Lilly, Spectrum, Summit; speaker: AstraZeneca, Blueprint, Genentech, Guardant, Janssen, Jazz, Lilly, Nuvation, Pharmacosmos, Regeneron.